A pivotal multicenter trial evaluating efficacy and safety of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with advanced basal cell carcinoma

A Pivotal Multicenter Trial Evaluating Efficacy and Safety of the Hedgehog Pathway Inhibitor (HPI) Vismodegib in Patients With Advanced Basal Cell Carcinoma (BCC)

European Journal of Cancer ◽

10.1016/s0959-8049(11)70096-x ◽

2011 ◽

Vol 47 ◽

pp. 2

Author(s):

L. Dirix ◽

M.R. Migden ◽

A.E. Oro ◽

A. Hauschild ◽

K. Lewis ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Multicenter Trial ◽

Hedgehog Pathway ◽

Efficacy And Safety ◽

Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Basal Cell Carcinoma (BCC): 12-Month Erivance BCC Study Update

Annals of Oncology ◽

10.1016/s0923-7534(20)33694-2 ◽

2012 ◽

Vol 23 ◽

pp. ix362 ◽

Cited By ~ 4

Author(s):

A. Sekulic ◽

M.R. Migden ◽

A. Oro ◽

K. Lewis ◽

J.D. Hainsworth ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Hedgehog Pathway ◽

Efficacy And Safety ◽

Abstract A44: Predictive biomarkers of efficacy to the hedgehog pathway inhibitor, GDC‐0449, in advanced basal cell carcinoma and medulloblastoma in phase I studies

10.1158/1535-7163.targ-09-a44 ◽

2009 ◽

Author(s):

Robert Yauch ◽

Thomas Januario ◽

Ling Fu ◽

Thomas Holcomb ◽

Jeremy Stinson ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Basal Cell ◽

Predictive Biomarkers ◽

Hedgehog Pathway ◽

Phase I Studies ◽

Characterization and Management of Hedgehog Pathway Inhibitor‐Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

The Oncologist ◽

10.1634/theoncologist.2016-0186 ◽

2016 ◽

Vol 21 (10) ◽

pp. 1218-1229 ◽

Cited By ~ 58

Author(s):

Mario E. Lacouture ◽

Brigitte Dréno ◽

Paolo Antonio Ascierto ◽

Reinhard Dummer ◽

Nicole Basset‐Seguin ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Adverse Events ◽

Cell Carcinoma ◽

Basal Cell ◽

Hedgehog Pathway ◽

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2013.09.012 ◽

2014 ◽

Vol 70 (1) ◽

pp. 60-69 ◽

Cited By ~ 106

Author(s):

Anne Lynn S. Chang ◽

James A. Solomon ◽

John D. Hainsworth ◽

Leonard Goldberg ◽

Edward McKenna ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Hedgehog Pathway ◽

Expanded Access ◽

Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma

Journal of the Advanced Practitioner in Oncology ◽

10.6004/jadpro.2014.5.4.7 ◽

2014 ◽

Vol 5 (4) ◽

Cited By ~ 1

Author(s):

Nancy M. Nix, PharmD, BCPS, BCOP ◽

Olivia Burdine, PharmD ◽

Makeda Walker, PharmD

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Locally Advanced ◽

Hedgehog Pathway ◽

Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.9532 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9532-9532 ◽

Cited By ~ 2

Author(s):

Johan Hansson ◽

Axel Hauschild ◽

Rainer Kunstfeld ◽

Jean Jacques Grob ◽

Brigitte Dréno ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Hedgehog Pathway ◽

Primary Analysis ◽

Clinical development of GDC-0449, a hedgehog pathway inhibitor, for the treatment of advanced basal cell carcinoma

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2009.11.409 ◽

2010 ◽

Vol 62 (3) ◽

pp. AB104

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Clinical Development ◽

Hedgehog Pathway ◽

Spontaneous resolution of advanced basal cell carcinoma after short-pulse treatment with hedgehog pathway inhibitor

JAAD Case Reports ◽

10.1016/j.jdcr.2016.06.010 ◽

2016 ◽

Vol 2 (4) ◽

pp. 360-361 ◽

Cited By ~ 3

Author(s):

Audrey A. Jacobsen ◽

John Strasswimmer

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Short Pulse ◽

Spontaneous Resolution ◽

Hedgehog Pathway ◽

Pulse Treatment ◽

Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy

Annals of Oncology ◽

10.1093/annonc/mdy288.111 ◽

2018 ◽

Vol 29 ◽

pp. viii440 ◽

Cited By ~ 2

Author(s):

K.D. Lewis ◽

M.G. Fury ◽

E. Stankevich ◽

M. Mathias ◽

K.K. Mohan ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Basal Cell ◽

Phase Ii Study ◽

Hedgehog Pathway ◽

Progression Of Disease ◽